Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Identifying and applying molecular subgrouping in colorectal cancer

WIN Symposium 2013

10 - 12 Jul 2013

Published: 18 Jul 2013

Views: 5377

Rating:

Save

Dr Sabine Tejpar - University of Leuven, Leuven, Belgium

Dr Sabine Tejpar talks to ecancer that 2013 WIN Symposium about understanding the patterns for treating colorectal cancer and drug development, including novel agents.

Filmed in Partnership with the WIN Consortium

Related Videos

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful...

Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients ( Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea )

Immunotherapy significantly increases the number of patients free from bowel...

Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK

Immunotherapy significantly increases the number of patients free from bowel cancer ( Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK )

ESMO 2023: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2023: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Potential benefit to response rates from trastuzumab added to perioperative...

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of...

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )

Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC

Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh...

Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC ( Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia )

Latest treatments in oesophageal cancer

Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA

Latest treatments in oesophageal cancer ( Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA )

Trifluridine/tipiracil plus bevacizumab improves OS in mCRC

Dr Josep Tabernero - Vall d’Hebron University Hospital, Barcelona, Spain

Trifluridine/tipiracil plus bevacizumab improves OS in mCRC ( Dr Josep Tabernero - Vall d’Hebron University Hospital, Barcelona, Spain )

More from ecancer